Skip to main content
ADMA
NASDAQ Life Sciences

反驳ADMA生物技术的误导性做空报告指控

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$11.63
Mkt Cap
$2.698B
52W Low
$10.9
52W High
$25.67
Market data snapshot near publication time

summarizeSummary

ADMA生物技术已经正式回应了Culper Research于2026年3月24日发布的做空报告，该报告披露了ADMA的做空头寸。该公司坚决驳斥该报告的说法，将其描述为“基于不可靠来源的推测性断言”，并且“包含许多误导性、虚假和不准确的陈述”。这一事件很重要，因为它直接挑战了ADMA的财务报告和运营披露的完整性。交易者将密切关注市场如何权衡这些指控与公司有力的驳斥。未来发展，包括任何一方的进一步细节或潜在的监管兴趣，将成为关键的催化剂。

在该公告发布时，ADMA的交易价格为$11.63，交易所为NASDAQ，所属行业为Life Sciences，市值约为$27亿。 52周交易区间为$10.90至$25.67。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ADMA - Latest Insights

ADMA
Apr 15, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ADMA Biologics Details Strong 2025 Performance, Executive Compensation, and Pipeline Progress in Definitive Proxy
Sentiment: Positive
View Wiseek Article
ADMA
Mar 28, 2026, 6:18 AM EDT
Source: Access Newswire
Importance Score:
7
Law Firm Investigates ADMA Biologics for Securities Fraud After 29% Stock Plunge
Sentiment: Negative
View Wiseek Article
ADMA
Mar 27, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Issues Detailed Rebuttal to Short-Seller Allegations with Supporting Data
Sentiment: Positive
View Wiseek Article
ADMA
Mar 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
ADMA Biologics Rejects Short-Seller Claims, Citing Strong ASCENIV Demand and Industry-Standard Inventory
Sentiment: Neutral
View Wiseek Article
ADMA
Mar 25, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Misleading Short-Seller Report Allegations Rebutted by ADMA Biologics
Sentiment: Negative
View Wiseek Article
ADMA
Mar 02, 2026, 7:13 AM EST
Source: Unknown
Importance Score:
8
ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of ~$200M 2026 Buyback Plan
Sentiment: Positive
View Wiseek Article
ADMA
Mar 02, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of $200M 2026 Capital Return Plan
Sentiment: Positive
View Wiseek Article
ADMA
Feb 25, 2026, 5:16 PM EST
Filing Type: 10-K
Importance Score:
8
ADMA Biologics Reports Record 2025 Financials, Driven by ASCENIV Growth and Strategic Initiatives
Sentiment: Positive
View Wiseek Article
ADMA
Feb 25, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Reports Record 2025 Financial Results, Strong 2026-2029 Guidance, and Smooth CFO Transition
Sentiment: Positive
View Wiseek Article
ADMA
Jan 12, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Raises 2026 Guidance, Projects Strong Long-Term Growth to $1.1B Revenue by 2029
Sentiment: Positive
View Wiseek Article